978 Stock Overview
A clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Adagene Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.90 |
| 52 Week High | US$3.66 |
| 52 Week Low | US$1.43 |
| Beta | 0.49 |
| 1 Month Change | -10.38% |
| 3 Month Change | -39.87% |
| 1 Year Change | 29.25% |
| 3 Year Change | -82.41% |
| 5 Year Change | n/a |
| Change since IPO | -90.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| 978 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.0% | -2.6% | -2.0% |
| 1Y | 29.3% | -13.2% | 6.8% |
Return vs Industry: 978 exceeded the German Biotechs industry which returned -14.7% over the past year.
Return vs Market: 978 exceeded the German Market which returned 6.9% over the past year.
Price Volatility
| 978 volatility | |
|---|---|
| 978 Average Weekly Movement | 14.5% |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 978's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 978's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 174 | Peizhi Luo | www.adagene.com |
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company’s product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs.
Adagene Inc. Fundamentals Summary
| 978 fundamental statistics | |
|---|---|
| Market cap | €87.21m |
| Earnings (TTM) | -€30.60m |
| Revenue (TTM) | €783.85k |
102.0x
P/S Ratio-2.6x
P/E RatioIs 978 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 978 income statement (TTM) | |
|---|---|
| Revenue | US$815.75k |
| Cost of Revenue | US$0 |
| Gross Profit | US$815.75k |
| Other Expenses | US$32.67m |
| Earnings | -US$31.85m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.72 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,904.31% |
| Debt/Equity Ratio | 36.3% |
How did 978 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 12:25 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Adagene Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Claire Wang | China Renaissance Securities |
| Bing Zhao | China Renaissance Securities |
| Ziyi Chen | Goldman Sachs |